Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry.
- DOI
- 10.1111/jdv.70009
- Published
- 2025 Dec
- Container
- Journal of the European Academy of Dermatology and Venereology : JEADV
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/jdv.70009,
title = {Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry.},
author = {Rob F and Gkalpakiotis S and Kojanová M and Vantuchová Y and Čelakovská J and Horažďovský J and Baláž M and Nečas M and Stuchlík D and Cetkovská P and Hrazdírová K and Machovcová A and Pinková B and Třešňák Hercogová J},
year = {2025},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
doi = {10.1111/jdv.70009},
url = {https://doi.org/10.1111/jdv.70009}
}RIS
TY - JOUR TI - Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry. AU - Rob F AU - Gkalpakiotis S AU - Kojanová M AU - Vantuchová Y AU - Čelakovská J AU - Horažďovský J AU - Baláž M AU - Nečas M AU - Stuchlík D AU - Cetkovská P AU - Hrazdírová K AU - Machovcová A AU - Pinková B AU - Třešňák Hercogová J PY - 2025 JO - Journal of the European Academy of Dermatology and Venereology : JEADV DO - 10.1111/jdv.70009 UR - https://doi.org/10.1111/jdv.70009 ER -
APA
F, R., S, G., M, K., Y, V., J, Č., J, H., M, B., M, N., D, S., P, C., K, H., A, M., B, P., & J, T. H. (2025). Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70009
Source records
- pubmed · retrieved 2026-09-26T06:23:35.618Z